Ardea Biosciences Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1994)
Status: Acquired by AstraZeneca (2012)

Organization Overview

First Clinical Trial
2008
NCT00617526
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ardea Biosciences, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

allopurinol (zyloprim) (11 trials)

Drugs in Phase 3 Trials (3)

Key: Ardea Biosciences (2) Acquired (1)

febuxostat (uloric) (4 trials)

iseganan (1 trial)

lesinurad (zurampic) (20 trials)

Drugs in Phase 2 Trials (3)

benzbromarone (1 trial)

rdea806 (2 trials)

verinurad (13 trials)

Drugs in Phase 1 Trials (7)

calcium carbonate (1 trial)

furosemide (lasix) (1 trial)

indomethacin (indocin) (1 trial)

magnesium hydroxide (1 trial)

naproxen (naprosyn) (1 trial)

ranitidine (zantac) (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gout (Phase 4)

HIV Infections (Phase 2)

Hyperuricemia (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 14